



Alliance for Clinical Trials in Oncology
Saturday, November 7, 2015
Loews Chicago O'Hare Hotel
9:00 am – 12:30 pm
Teleconf #: 1-800-501-8979
Access code: 3057352

Neuro-Oncology Committee Meeting Agenda

Chairs: Evanthia Galanis, MD

Welcome – Overview

E. Galanis

Neurooncology Branch at the National Institutes of Health

M. Gilbert

Newly Diagnosed GBM

Active Protocols

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation J. Sarkaria

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 in Newly Diagnosed Glioblastoma Following Resection and Chemoradiation. P.Wen

Phase I/II Study of AZD1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma B. Alexander
E. Galanis

Recently Completed Trials

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA]Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Concepts

ECOG-ACRIN EAF131(E1F13) study :Phase III Non-Inferiority Trial Comparing Radiation with Concurrent Temozolomide with or without Six Months of Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. L. Kleinberg
D. Schiff

Recurrent GBM

Active Protocols

A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) O. Bloch
I. Parney

Recently Completed Trials

N1174: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Accrual goal met 9/4/2015)

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14)

New Concepts

A Phase II Study of Anti-PD-1/PD-L1 Blockade Immunotherapy in Patients with Hypermutated Recurrent Glioblastoma G. Dunn

Anaplastic Gliomas – Newly Diagnosed

N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma K. Jaeckle

EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial K. Jaeckle

Low Grade Gliomas

E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (Temp. Closed) D. Schiff

Meningiomas

A071401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations P. Brastianos

Craniopharyngiomas

A071501: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas P. Brastianos

Brain Metastases

Active Protocols

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases P. Brown

Recently Completed Trials

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT)

Concepts

Molecularly-driven trial in brain metastases P. Brastianos

Nomogram-based Selection of Patients with 5-10 Brain Metastases for Stereotactic Radiosurgery vs Whole Brain Irradiation: A randomized trial M. Chan
P. Brown

Symptom Control

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis after Radiosurgery: A Randomized Phase II Trial C. Chung

Acknowledgement